This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (7)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Public Health  • Substance Abuse/ Alcoholism  • Alert me on articles by topic

Love at First Site

Arch Gen Psychiatry. 1999;56:1107-1108.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A NEW clinical study by Romach et al¹ reports that the D1 selective antagonist ecopipam (SCH 39166) blocks the subjective effects of intravenous cocaine in patients with a diagnosis of cocaine dependence. Using a randomized double-blind placebo-controlled design, ecopipam administered to humans 2 hours prior to an intravenous injection of 30 mg of cocaine dose-dependently blocked the subjective effects of cocaine. These doses of ecopipam did not block the effects of cocaine on heart rate or produce any other untoward effects. These are very exciting observations for 2 reasons. First, the results suggest that a dopamine-selective D1 dopaminergic antagonist is effective in humans in blocking the psychotropic effects of cocaine and second, these observations begin to validate a wealth of preclinical data suggesting powerful cocaine antagonistic effects of dopamine D1 antagonists.

Early observations in rats showed that the D1 antagonist SCH 23390 decreased the reinforcing properties of cocaine as measured . . . [Full Text of this Article]

RELATED ARTICLE

Attenuation of the Euphoric Effects of Cocaine by the Dopamine D1/D5 Antagonist Ecopipam (SCH 39166)
Myroslava K. Romach, Paul Glue, Kyle Kampman, Howard L. Kaplan, Gail R. Somer, Sabrina Poole, Laura Clarke, Vicki Coffin, James Cornish, Charles P. O'Brien, and Edward M. Sellers
Arch Gen Psychiatry. 1999;56(12):1101-1106.
ABSTRACT | FULL TEXT